1 # A review of research progress into adipose tissue macrophages
2 # and insulin resistance

3 **Mengfei Fu[1,2], Liu Yang[1,2], Hanyu Wang[1,2],Yang Chen[1,2], Xiao Chen[1,2]， Qinyu**
4 **Hu[1,2]， Hui Sun[1,2*]**

5 [1]Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong
6 University of Science and Technology, Wuhan, China

7 [2]Hubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders,
8 Wuhan, China
9 *** Correspondence:**
10 Hui Sun
11 sunny68@hust.edu.cn
12 **Short title:**
13 Research progress of ATMs and IR
14

Abstract

In recent years, there has been an increasing incidence of metabolic syndrome, type 2 diabetes, and cardiovascular events related to insulin resistance. As one of the target organs for insulin, adipose tissue is essential for maintaining *in vivo* immune homeostasis and metabolic regulation. Currently, the specific adipose tissue mechanisms involved in insulin resistance remain incompletely understood. There is increasing evidence that the process of insulin resistance is mostly accompanied by a dramatic increase in the number and phenotypic changes of adipose tissue macrophages (ATMs). In this review, we discuss the origins and functions of ATMs, some regulatory factors of ATM phenotypes, and the mechanisms through which ATMs mediate insulin resistance. We explore how ATM phenotypes contribute to insulin resistance in adipose tissue. We expect that modulation of ATM phenotypes will provide a novel strategy for the treatment of diseases associated with insulin resistance.
Keywords: insulin resistance; adipose tissue; inflammation; adipose tissue macrophages; phenotype

Introduction

Insulin resistance (IR) refers to a pathological state in which tissues such as adipose tissue, liver, and skeletal muscle, develop impaired sensitivity or responsiveness to insulin. IR is an important mechanism underlying the development of metabolic syndrome, type 2 diabetes mellitus (T2DM), cardiovascular events, and other diseases [1-3]. Its presence is characterized by a long-lasting chronic low-grade inflammatory state in the body [4, 5]. As such, IR-associated inflammation has garnered significant research interest as a potential therapeutic target for IR-associated diseases.

Existing studies have found that adipose tissue (AT), one of the target organs of insulin, is not only a storehouse of energy but also an active endocrine organ that can secrete a variety of bioactive molecules. Through this, AT participates in the metabolic processes of the body and alters insulin sensitivity locally and systemically [6]. AT consists of adipocytes and a stromal vascular fraction (SVF). The SVF is composed of endothelial cells, fibroblasts, and various immune cells such as macrophages, T cells, and B cells, thus underscoring its immunological and metabolic (immune metabolism) functions [6, 7].

Adipose tissue macrophages (ATMs) make up the largest proportion of AT immune cells and are indispensable for maintaining their function. In the pathogenesis of obesity, IR, and T2DM, ATMs can increase their numbers by 5-10 fold through peripheral cell recruitment and local proliferation [8, 9]. Accompanying these changes, the intrinsically highly malleable macrophages can alter their phenotype in response to cues from the local microenvironment, thereby altering their function [10]. As such, ATMs have become recognized to be key players in the development of inflammation and IR in AT [11] and form an important hub between immunity and metabolism.

In this review, we comprehensively investigate the relationship between ATMs, inflammation, and IR, with a focus on elucidating the regulatory factors associated with phenotypic changes in ATMs and the specific mechanisms mediating the development of IR in AT.

Origin and function of ATMs

In 1969, the classical model of the "mononuclear phagocyte system " was proposed. Based on the morphology, function, and origin of cells, promonocytes and their precursors in bone marrow, monocytes in peripheral blood, and macrophages in tissues were incorporated into the model [12]. In addition, a more primitive view has been formed of the origin of tissue macrophages, which are derived from circulating bone marrow-derived monocytes that migrate to tissues where they mature into macrophages, including Kupffer cells of the liver, alveolar macrophages, and ATMs [13]. Initially, tissue macrophages were regarded to be terminally differentiated cells, however, with later scientific advances and the availability of genetic fate mapping technologies, scientists gradually realized the importance of the yolk sac, an extra-embryonic hematopoietic site, for the generation of tissue macrophages. There, erythro-myeloid progenitors undergo a pro-macrophage differentiation stage to become macrophages[14, 15]. Therefore, the current consensus is that macrophages can be broadly dichotomized into monocyte-derived macrophages and tissue-derived macrophages based on their origin [16].

In inflammatory states, tissue-produced chemokines attract circulating monocytes and induce their differentiation into macrophages, leading to their local infiltration. However, the dramatic increase in the number of tissue macrophages does not depend solely on this process. Local *in situ* proliferation of ATMs driven by monocyte chemotactic protein-1 (MCP-1) contributes significantly to the local accumulation of macrophages in AT [17]. As such, both monocyte infiltration and local macrophage proliferation play a crucial role in the accumulation of ATMs under inflammatory conditions.

Macrophages are functionally diverse and involved in physiological and pathological processes such as organism development, tissue repair, immunomodulation, and maintenance of homeostasis in the body [18]. The macrophage surface is littered with pattern recognition receptors that recognize the molecular programs expressed by microorganisms and damaged cells, namely pathogen-associated molecular patterns and damage-associated molecular patterns, respectively. Macrophages exhibit a prodigious capacity for phagocytosis, wrapping and engulfing invading pathogens and presenting them to adaptive immune response cells as part of the innate immune response[19, 20]. Thereby, macrophages play an *in vivo* role in immune surveillance, immune defense, and immune self-stabilization.

In addition to pathogens, macrophages also use phagocytosis to remove senescent cells from the body, thereby enabling cellular self-renewal and regulation. These functions are preserved in the AT. The total number of adipocytes is determined during childhood and adolescence and is maintained within a relatively stable range in adulthood. Spalding KL *et al.* demonstrated that approximately 10% of fat cells are

100 renewed annually throughout adulthood, independent of the body mass index
101 (BMI)[21]. Cell renewal is also active in AT and is characterized by the continuous
102 removal and replacement of adipocytes. Macrophages play a key role in this process.
103 Necrotic adipocytes can recruit large numbers of macrophages to encircle them
104 in crown-like structures (CLS) (Figure 1). Having done this, macrophages then
105 remove any dead adipocyte residue. The process of removing necrotic adipocytes by
106 ATMs is thought to be a critical step in the repair and remodeling of AT [22]. In
107 addition, recruited macrophages also secrete pro-inflammatory cytokines that mediate
108 inflammation[23]. Thus, to some extent, the presence of CLS is considered to be one
109 of the markers of a pro-inflammatory state in AT. To clarify the relationship between
110 systemic IR and subcutaneous and visceral adipose inflammation, Bigornia SJ *et al.*
111 evaluated the CLS in AT as a marker of chronic inflammation and found a significant
112 positive correlation between the presence of CLS and IR [24], indirectly confirming
113 the important role of ATMs in IR.
114 In summary, ATMs are derived from the differentiation of yolk sac progenitor
115 cells and the migration of circulating monocytes, which are essential for the immune
116 regulation of the body. ATMs achieve self-renewal of AT through their powerful
117 phagocytic capacity and maintain AT homeostasis by removing necrotic adipocytes to
118 repair and remodel AT.

119 **ATM Phenotypes**

120 In response to the microenvironment, macrophages can rapidly adapt by
121 increasing in numbers and altering their phenotype and function [25, 26]. Classically,
122 macrophages are dichotomously classified into activated M1 macrophages or
123 alternatively-activated M2 macrophages. M1 macrophages are activated by
124 interferon-γ (IFN-γ), lipopolysaccharide (LPS), and tumor necrosis factor (TNF) and
125 have a high antigen-presenting capacity as well as high phagocytic and bactericidal
126 functions. They release various pro-inflammatory cytokines such as interleukin-6(IL-
127 6), TNF-α, IL-12, reactive oxygen species (ROS), and nitric oxide (NO) that further
128 activate inflammatory responses[27]. M2 macrophages can release multiple anti-
129 inflammatory cytokines such as IL-10, transforming growth factor-β (TGF-β), and
130 interleukin-1 receptor antagonist (IL-1ra) to suppress the inflammatory response and
131 promote tissue repair [28, 29]. M2 macrophages are further subdivided into four
132 subtypes, M2a, M2b, M2c, and M2d, depending on external stimuli and their
133 functions[30, 31]. M2a (wound healing macrophages) are induced by interleukins (IL-
134 4, IL-13), M2b (regulatory macrophages) are induced by exposure to immune
135 complexes (ICs) and Toll-like receptor (TLR) ligands or agonists of IL-1R, M2c
136 (acquired inactivated macrophages) are induced by IL-10, TGF-β, and
137 glucocorticoids[32, 33], and M2d (tumor-associated macrophages) are induced by
138 TLR ligands and A2 adenosine receptor (A2R) agonists or IL-6 co-stimulation[34-
139 36](Figure 2).
140 Transcriptional profiling has deepened our understanding of macrophage
141 plasticity, showing that macrophage responses to stress signals involve complex
142 cellular programs [37]. In the normal state, tissue macrophages predominantly exhibit

the M2 subtype and help maintain the internal tissue homeostatic environment. However, in the inflammatory state, the phenotype of macrophages becomes altered. In the early stages of inflammation, M1 macrophages predominate while the late stages of inflammation are associated with the M2 macrophage phenotype [38]. In addition, in metabolic disease, ATMs present a complex phenotype that cannot be classified as M1 or M2; such cells are referred to as metabolically activated macrophages. These cells express lower levels of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6 than M1 macrophages, and similarly low levels of CD206 as M2 macrophages. The emergence of the "metabolic activation" state is mainly associated with palmitate. On the one hand, palmitate binds to TLRs on the cell surface, driving the production of pro-inflammatory cytokines. On the other hand, palmitate is internalized by macrophages, activating p62 and PPARγ, thereby promoting lipid metabolism and suppressing inflammation. The balance between these two mechanisms determines the overall macrophage response to metabolic dysfunction[39, 40]. Thus, it can be seen that macrophages can rapidly switch to unique phenotypes, based on microenvironmental cues, that facilitate the performance of diverse functions during the different stages of non-inflammatory and inflammatory conditions [41].

Factors regulating the ATM phenotypes

1. TLR4

Toll-like receptors (TLRs) are pattern recognition receptors that trigger the activation of pro-inflammatory signaling pathways such as NF-κB, leading to the release of inflammatory molecules such as cytokines and chemokines. Each TLR plays a unique and critical role in innate immunity [42-44]. TLR4 stands at the cross-roads of nutrition, lipids, and immunity. TLR4 is a major endogenous receptor for LPS[45]; LPS is also an important stimulant of the M1 macrophage phenotype. As such, TLR4 may regulate the ATM phenotype. TLR4 mRNA was shown to be significantly elevated in the AT of obese mice. This study also pointed out that the TLR4 signaling pathway also mediates the process of free fatty acid-induced macrophage inflammation[46]. A significant increase in TLR4 mRNA expression has also been observed in the visceral fat of obese patients[47].

Exercise training has been shown to modulate the ATM phenotype in obese mice, and may inhibit inflammation in AT by downregulating TLRs [48]. Shan B *et al.* showed that TLR4 signaling in perivascular stromal cells is an important mediator of pro-inflammatory macrophage accumulation in white adipose tissue (WAT) [49]. By constructing a TLR4-specific knockout mouse model, Orr JS *et al*. found that TLR4 deficiency promotes the polarization of ATMs toward the M2 phenotype and thereby promotes the activation of alternative macrophages and reduces inflammation in AT[50]. In addition, Griffin C and colleagues found that a high-fat diet affects macrophage proliferation and polarization by enhancing TLR4 expression in AT and its downstream signaling [51]. In conclusion, the aforementioned studies suggest that

184 TLR4 signaling plays an important role in the local proliferation and phenotypic
185 transformation of ATMs.

186 2. ROS

187 The redox status in the body significantly affects the macrophage phenotype.
188 Reactive oxygen species (ROS), a direct product of oxidative stress, have been shown
189 to promote the activation of the NOD-like receptor protein 3(NLRP3) inflammasome
190 and other inflammatory responses in macrophages and are important mediators of
191 pro-inflammatory signaling pathways [52]. Free fatty acids (FFA), which regulate M1
192 polarization *in vitro*, are closely associated with increased ROS production and
193 macrophage recruitment[53]. However, several studies have reported inconsistent
194 effects of ROS on the macrophage phenotype. In the presence of high glucose, ROS
195 promotes M1 macrophage polarization by impairing the autophagy-lysosome system
196 [54]. Acin-Perez R *et al.* found that the ROS scavenger NAC significantly increased
197 the proportion of M1 macrophages in WAT, showing that ROS promotes M1
198 polarization[55]. Others have demonstrated that oleanolic acid, a natural triterpenoid,
199 inhibits the activation of the NLRP3 inflammasome by reducing ROS production,
200 thereby inhibiting M1 polarization and improving adipose chronic inflammation and
201 IR[56]. However, Wang Y *et al.* characterized a near-infrared fluorophore (IR-61) that
202 preferentially accumulates in ATMs and demonstrated that it enhances the content and
203 activity of the mitochondrial complex of ATMs via the ROS-Akt-Acly pathway,
204 thereby inhibiting M1 macrophage activation[57]. Thus, ROS plays an important role
205 in regulating the phenotypic transformation of macrophages, but its specific
206 contextual mechanisms of action still need to be explored in more depth.
207 ROS includes superoxide, hydrogen peroxide, and hydroxyl radicals, and its
208 sources are mitochondria, NADPH oxidase, peroxisomes, and the endoplasmic
209 reticulum [58]. Among them, mitochondria, as the main sites of biological oxidation
210 and energy conversion, are the main sources of ROS production [59]. Mitochondrial
211 ROS impacts the metabolic processes of proteins, lipids, glucose, and other energetic
212 substances [60]. It has been widely demonstrated that changes in lipid metabolism
213 play an important role in regulating the phenotypic transformation of ATMs.
214 Macrophages in the AT of lean animals mostly exhibit the M2 subtype. In contrast, in
215 obese animals, ATMs are mostly of the M1 subtype [61]. Lumeng CN *et al.* isolated
216 SVF from excised epididymal fat pads of male mice fed a normal diet and a high-fat
217 diet and found that diet-induced obesity resulted in the conversion of ATMs from the
218 M2 subtype to the M1 subtype [62]. In obese states, the reduced lipid storage
219 efficiency of WAT and the release of lipids from adipocytes create a lipid-rich
220 microenvironment for ATMs. In addition, the expression of very low-density
221 lipoprotein receptors (VLDLR) is increased in obese ATMs. Activation of these
222 receptors by VLDL causes an increase in intracellular triglyceride levels, ultimately
223 leading to the polarization of ATMs toward the M1 pro-inflammatory subtype, leading
224 to the development of IR[63].

225 3. KLF4

226 Kruppel-like factors (KLFs) are a subfamily of zinc finger-like DNA-binding
227 transcriptional regulators involved in cell growth, proliferation, and differentiation
228 [64, 65]. KLF4 was isolated from the NIH 3T3 library and named the intestinal
229 enrichment Kruppel-like factor, a well-studied member of the KLF family. Ectopic
230 expression of KLF4 induces macrophage maturation. In addition, KLF4 has been
231 shown to mediate IL-4-induced M2 macrophage polarization and inhibit
232 inflammatory signaling. KLF4 regulates key signaling pathways that control
233 macrophage activation and regulates the macrophage phenotype [66].
234 Obese patients have been found to express 50% less KLF4 in AT than lean
235 patients; a similar phenomenon was found in isolated SVF. In addition, this study also
236 evaluated the expression of M1 and M2 macrophages marker genes in SVF of wild
237 mice fed a high-fat diet and myeloid KLF4 knockout mice, finding that KLF4 is a
238 novel regulator of macrophage polarization and that its deficiency may affect the
239 ATM phenotype [67]. There was a significant negative correlation between miR-34a
240 and KLF4 mRNA expression in adipocyte-secreted exosomes. miR-34a inhibited the
241 polarization of ATMs to the M2 subtype by suppressing KLF4 expression, and
242 conversely, KLF4 overexpression significantly decreased the expression of M1
243 macrophage markers and enhanced the expression of M2 macrophage markers [68].
244 In addition, transfection of bone marrow-derived macrophages using miR375
245 inhibitors confirmed that the effect of miR375 on macrophage polarization was at
246 least partially mediated by KLF4 [69]. Using a high-fat diet-induced IR model, Luan
247 B *et al.* verified that macrophage cyclic-AMP response binding protein (CREB)
248 promotes macrophage polarization towards the M2 subtype by upregulating KLF4,
249 thereby protecting AT from IR in the context of obesity[70]. These studies highlight
250 the importance of KLF4 as an important regulatory molecule for the polarization of
251 ATMs.

252 4. PPARγ

253 The transcription factor peroxisome proliferator-activated receptor-γ (PPARγ)
254 belongs to the family of ligand-dependent nuclear receptors and is the target of action
255 of the insulin sensitizer thiazolidinedione drugs for the treatment of T2DM [71]. In
256 1998, PPARγ was found to be expressed in macrophages and scholars have since
257 worked to better understand its role in macrophage activation and metabolism [72].
258 PPARγ has now been confirmed to be involved in the differentiation, infiltration, and
259 polarization of macrophages and to play a critical role in the IL-4 stimulation of
260 macrophages [73]. IL-4 was found to induce the expression of surface markers of
261 alternatively activated macrophages in a PPARγ-dependent manner and that deletion
262 of the PPARγ gene in macrophages increases M1-subtype ATM cells and IR in AT
263 [74, 75].
264 The combined effect of PPARγ and its ligand rosiglitazone significantly
265 enhanced the ability of IL-4 to activate the arginase I promoter, suggesting that
266 PPARγ is directly involved in the regulation of macrophage activation[75]. Previous
267 studies found that PPARγ expression is significantly lower in the AT of mice fed a
268 high-fat diet compared to mice fed a regular diet. A high-fat diet leads to the

269 recruitment of more M1 macrophages, in part by downregulating PPARγ, thereby
270 maintaining a chronic inflammatory state in AT during obesity[76]. PPARγ is a key
271 regulator of alternative macrophage polarization and interferon regulatory factor 6
272 (IRF6) was shown to inhibit M2 macrophage polarization by directly downregulating
273 PPARγ expression in macrophages; the effect of the IRF6/PPARγ regulatory axis on
274 the ATM phenotype provides a theoretical basis for the study of metabolism and
275 immune regulation in obese AT [77]. Furthermore, recent evidence suggests that
276 PPARγ expression is significantly decreased in the epididymal AT of high-fat fed
277 C57BL/6J obese mice and that ginsenoside compound K improves IR by upregulating
278 PPARγ expression, regulating macrophage polarization, and reducing the release of
279 inflammatory factors [78]. These findings suggest that PPARγ modulation of the ATM
280 phenotype is a potentially important target for improving IR, which is mainly
281 characterized by chronic low-grade inflammation.
282 In brief, macrophage phenotypes are susceptible to regulation by the local
283 microenvironment. TLR4, ROS, KLF4, and PPARγ have been repeatedly shown to be
284 involved in the phenotypic regulation of ATMs. Among these, TLR4 mediates the
285 polarization of ATMs to the M1 subtype, which also regulates the local proliferation
286 of macrophages. KLF4 and PPARγ regulate the polarization of ATMs to the M2
287 subtype, reduce the release of pro-inflammatory factors, and improve IR. How ROS
288 affects the macrophage phenotype and the underlying mechanisms of action are not
289 yet fully understood.
290

291 **Mechanisms of ATM-mediated insulin resistance**

292 Insulin signaling pathway

293 Insulin binds to cell surface insulin receptors and subsequently activates tyrosine
294 kinase, which further causes phosphorylation of insulin receptor substrate (IRS). The
295 phosphorylation of key tyrosine residues of IRS exposes the binding site, which is
296 recognized and bound by phosphatidylinositol 3 kinase (PI3K). PI3K then
297 phosphorylates PIP2 to PIP3, which binds to AKT and 3-phosphoinositide-dependent
298 protein kinase-1 (PDK1), prompting PDK1 to phosphorylate the AKT protein leading
299 to AKT activation [79, 80]. Akt activation regulates intracellular glucose transporter 4
300 (GLUT4) translocation to the plasma membrane, mediating the transport of glucose
301 [81, 82]. In AT, activation of the PI3K/Akt signaling pathway also inhibits
302 phosphodiesterase 3B (PDE3B), protein phosphatase 1(PP1), and protein phosphatase
303 2A (PP2A) and inhibits lipolysis, which in turn inhibits hepatic gluconeogenesis[83]
304 (Figure 3).

305 M1 ATMs promote insulin resistance

306 The altered insulin sensitivity in AT is closely related to the macrophage
307 phenotype; the conversion of macrophages from an M2 anti-inflammatory phenotype
308 to an M1 pro-inflammatory phenotype is thought to be the main cause of reduced
309 insulin sensitivity [84]. The process of macrophage-mediated IR is a "double

310 whammy". First, there is an activation of tissue macrophages; in this case, we refer
311 specifically to the activation of ATMs which release pro-inflammatory cytokines.
312 Second, there is an activation of inflammatory signaling pathways within neighboring
313 insulin target cells (adipocytes), leading to the development of IR [85]. Various pro-
314 inflammatory cytokines such as TNF-α and IL-6 produced by M1 ATMs can be
315 directly involved in the development of IR, and the activation of inflammatory
316 signaling can enhance the effects of IR.

317 1. TNF-α

318 Using the glucose tolerance test as an index to evaluate insulin sensitivity, Kern
319 PA *et al.* found a significant positive correlation between the levels of TNF-α and IR
320 severity [86]. TNF-α reduces the expression of GLUT4, the most abundant glucose
321 transporter protein in adipocytes, which can directly affect the insulin-regulated
322 glucose transport process [87]. TNF-α can also promote the accumulation of ceramide
323 by activating the activity of sphingomyelinase that catalyzes the hydrolysis of
324 sphingolipids to ceramide, which is thought to be an important mediator linking TNF-
325 α to IR. In addition, TNF-α has been shown to reduce the levels of adiponectin
326 (ADPN) *in vitro* [88], which is the most abundant adipocytokine in plasma and has a
327 direct positive effect on tissue insulin sensitivity. On the other hand, ADPN has also
328 been found to indirectly affect tissue insulin sensitivity by promoting exosome
329 secretion, which leads to a decrease in ceramide production [89]. In addition, TNF-α
330 impairs insulin sensitivity in AT by inducing serinephosphorylation of insulin receptor
331 substrate-1 (IRS-1), a key substrate for insulin signaling. Activated IRS-1 binds to
332 PI3K and activates downstream signaling; once some sites (such as serine 307) of
333 IRS-1 are phosphorylated, insulin signaling is diminished[90].

334 2. IL-6

335 ATMs are a major source of IL-6 in AT. IL-6 is a pro-inflammatory cytokine that
336 is closely associated with the development of inflammation and IR. Elevated IL-6
337 levels independently predict T2DM [91]. IL-6 has been shown to induce IR through
338 multiple pathways. Chronically elevated IL-6 induces the expression of suppressor of
339 cytokine signaling 3 (SOCS 3); its overexpression impairs downstream signaling by
340 inhibiting tyrosine phosphorylation of IRS proteins, thereby causing IR [92]. Like
341 TNF-α, IL-6 represses the gene transcription of IRS-1 and GLUT4, and the reduced
342 expression of these genes and proteins directly leads to impaired insulin signaling and
343 an imbalance of glucose homeostasis [88, 93]. IL-6 has also been shown to negatively
344 correlate with ADPN levels; following co-incubation of AT with IL-6 and the soluble
345 receptor, ADPN mRNA expression was significantly reduced [94]. However, several
346 studies have shown that IL-6 does not exclusively act as a negative regulator of
347 insulin signaling. Stanford KI *et al.* found that elevated circulating IL6 increased
348 energy expenditure, reduced obesity, and improved systemic glucose metabolism[95],
349 which is consistent with previous findings[96]. Currently, the controversial
350 relationship between IL-6 and IR and glucose metabolism can be explained partly by

the response time of IL-6. Chronic elevation of IL-6 leads to the development of IR and, conversely, acute elevation of IL-6 enhances insulin sensitivity[91].The specific mechanisms involved in IL-6 regulation of insulin sensitivity in AT need to be further clarified.

In short, M1 macrophages can secrete pro-inflammatory factors such as TNF-α and IL-6 leading to the development of IR. TNF-α can eventually cause IR by reducing the expression of GLUT4 and adiponectin, increasing the level of ceramide, and inducing IRS-1 serine phosphorylation. IL-6 has similar effects, and can also indirectly inhibit the tyrosine phosphorylation of IRS proteins leading to IR by inducing the expression of SOCS-3. The role of IL-6 in regulating insulin sensitivity in AT remains controversial.

Summary

The specific mechanisms of IR in AT remain incompletely understood. There is increasing evidence that chronic inflammation plays an important role in the development of IR. At the same time, the role of tissue-resident immune cells in inflammation and IR cannot be ignored. The relationship between ATMs, as the most abundant immune cells in AT, and IR has been widely explored. The most studied of these involve the phenotypic changes of ATMs. The regulatory factors of the ATM phenotypes and the specific mechanisms through which ATMs mediate IR in AT are ongoing topics of research. Modulation of the ATM phenotype by various technical means may ultimately allow us to improve the treatment of inflammation and IR in AT.

Disclosures

No conflicts of interest,financial or otherwise,are declared by the authors.

Author Contributions

H.S. conceived the study. M.F. prepared figures and drafted manuscript. L.Y., H.W.,Y.C., X.C., and Q.H. edited and revised manuscript. All authors approved the final version of manuscript.

Acknowledgements

The authors would like to express their gratitude to EditSprings (https://www.editsprings.cn) for the expert linguistic services provided.

References

388 1. Hill MA, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and
389 cardiovascular disease. *Metabolism*. Jun 2021;119:154766.
390 2. Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms
391 and Clinical Disease. *Hypertension*. Nov 2021;78(5):1197-1205.
392 3. Lemieux I, Despres JP. Metabolic Syndrome: Past, Present and Future. *Nutrients*.
393 Nov 14 2020;12(11).
394 4. Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune
395 cells in dysfunctional adipose tissue. *Cardiovasc Res*. Jul 1 2017;113(9):1009-1023.
396 5. Lee YS, Olefsky J. Chronic tissue inflammation and metabolic disease. *Genes*
397 *Dev*. Mar 1 2021;35(5-6):307-328.
398 6. Grant RW, Dixit VD. Adipose tissue as an immunological organ. *Obesity (Silver*
399 *Spring)*. Mar 2015;23(3):512-8.
400 7. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens*
401 *Rep*. Feb 26 2018;20(2):12.
402 8. Lee YS, Wollam J, Olefsky JM. An Integrated View of Immunometabolism. *Cell*.
403 Jan 11 2018;172(1-2):22-40.
404 9. Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in
405 obesity. *Immunology*. Dec 2018;155(4):407-417.
406 10. Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The Metabolic
407 Signature of Macrophage Responses. *Front Immunol*. 2019;10:1462.
408 11. Orliaguet L, Ejlalmanesh T, Alzaid F. Metabolic and Molecular Mechanisms of
409 Macrophage Polarisation and Adipose Tissue Insulin Resistance. *Int J Mol Sci*. Aug
410 10 2020;21(16).
411 12. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL.
412 The mononuclear phagocyte system: a new classification of macrophages, monocytes,
413 and their precursor cells. *Bull World Health Organ*. 1972;46(6):845-52.
414 13. Mass E. Delineating the origins, developmental programs and homeostatic
415 functions of tissue-resident macrophages. *Int Immunol*. Oct 29 2018;30(11):493-501.
416 14. Mass E, Ballesteros I, Farlik M, et al. Specification of tissue-resident
417 macrophages during organogenesis. *Science*. Sep 9 2016;353(6304).
418 15. Palis J, Robertson S, Kennedy M, Wall C, Keller G. Development of erythroid
419 and myeloid progenitors in the yolk sac and embryo proper of the mouse.
420 *Development*. Nov 1999;126(22):5073-84.
421 16. Perdiguero EG, Geissmann F. The development and maintenance of resident
422 macrophages. *Nat Immunol*. Jan 2016;17(1):2-8.
423 17. Amano SU, Cohen JL, Vangala P, et al. Local proliferation of macrophages
424 contributes to obesity-associated adipose tissue inflammation. *Cell Metab*. Jan 7
425 2014;19(1):162-171.
426 18. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development,
427 homeostasis and disease. *Nature*. Apr 25 2013;496(7446):445-55.
428 19. Hirayama D, Iida T, Nakase H. The Phagocytic Function of Macrophage-
429 Enforcing Innate Immunity and Tissue Homeostasis. *Int J Mol Sci*. Dec 29
430 2017;19(1).
431 20. Rosales C, Uribe-Querol E. Phagocytosis: A Fundamental Process in Immunity.

432 *Biomed Res Int*. 2017;2017:9042851.
433 21. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in
434 humans. *Nature*. Jun 5 2008;453(7196):783-7.
435 22. Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue
436 remodeling, and obesity complications. *Diabetes*. Dec 2007;56(12):2910-8.
437 23. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage
438 localization and function in adipose tissue of obese mice and humans. *J Lipid Res*.
439 Nov 2005;46(11):2347-55.
440 24. Bigornia SJ, Farb MG, Mott MM, et al. Relation of depot-specific adipose
441 inflammation to insulin resistance in human obesity. *Nutr Diabetes*. Mar 5
442 2012;2:e30.
443 25. Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-Induced Macrophage
444 Polarization in Inflammatory Conditions. *Front Immunol*. 2018;9:1930.
445 26. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J*
446 *Clin Invest*. Mar 2012;122(3):787-95.
447 27. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory
448 diseases. *Int J Biol Sci*. 2014;10(5):520-9.
449 28. Bashir S, Sharma Y, Elahi A, Khan F. Macrophage polarization: the link between
450 inflammation and related diseases. *Inflamm Res*. Jan 2016;65(1):1-11.
451 29. Saha S, Shalova IN, Biswas SK. Metabolic regulation of macrophage phenotype
452 and function. *Immunol Rev*. Nov 2017;280(1):102-111.
453 30. Ferrante CJ, Leibovich SJ. Regulation of Macrophage Polarization and Wound
454 Healing. *Adv Wound Care (New Rochelle)*. Feb 2012;1(1):10-16.
455 31. Roszer T. Understanding the Mysterious M2 Macrophage through Activation
456 Markers and Effector Mechanisms. *Mediators Inflamm*. 2015;2015:816460.
457 32. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine
458 system in diverse forms of macrophage activation and polarization. *Trends Immunol*.
459 Dec 2004;25(12):677-86.
460 33. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and
461 polarization. *Front Biosci*. Jan 1 2008;13:453-61.
462 34. Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in
463 atherosclerosis. *Immunol Rev*. Nov 2014;262(1):153-66.
464 35. Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor
465 and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.
466 *Blood*. Dec 15 2007;110(13):4319-30.
467 36. Wang Q, Ni H, Lan L, Wei X, Xiang R, Wang Y. Fra-1 protooncogene regulates
468 IL-6 expression in macrophages and promotes the generation of M2d macrophages.
469 *Cell Res*. Jun 2010;20(6):701-12.
470 37. Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals
471 a spectrum model of human macrophage activation. *Immunity*. Feb 20
472 2014;40(2):274-88.
473 38. Dey A, Allen J, Hankey-Giblin PA. Ontogeny and polarization of macrophages in
474 inflammation: blood monocytes versus tissue macrophages. *Front Immunol*.
475 2014;5:683.

476 39. Kratz M, Coats BR, Hisert KB, et al. Metabolic dysfunction drives a
477 mechanistically distinct proinflammatory phenotype in adipose tissue macrophages.
478 *Cell Metab*. Oct 7 2014;20(4):614-25.
479 40. Puschel GP, Klauder J, Henkel J. Macrophages, Low-Grade Inflammation,
480 Insulin Resistance and Hyperinsulinemia: A Mutual Ambiguous Relationship in the
481 Development of Metabolic Diseases. *J Clin Med*. Jul 27 2022;11(15).
482 41. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of
483 localization and functional polarization of macrophages. *Cell*. May 8
484 2014;157(4):832-44.
485 42. Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past,
486 present, and future. *Int Immunopharmacol*. Jun 2018;59:391-412.
487 43. Brennan JJ, Gilmore TD. Evolutionary Origins of Toll-like Receptor Signaling.
488 *Mol Biol Evol*. Jul 1 2018;35(7):1576-1587.
489 44. Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like
490 receptors: Significance, ligands, signaling pathways, and functions in mammals. *Int*
491 *Rev Immunol*. Jan 2 2018;37(1):20-36.
492 45. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Increased tenascin C and Toll-
493 like receptor 4 levels in visceral adipose tissue as a link between inflammation and
494 extracellular matrix remodeling in obesity. *J Clin Endocrinol Metab*. Oct
495 2012;97(10):E1880-9.
496 46. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. *Curr Opin*
497 *Immunol*. Feb 2000;12(1):20-6.
498 47. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate
499 immunity and fatty acid-induced insulin resistance. *J Clin Invest*. Nov
500 2006;116(11):3015-25.
501 48. Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits
502 inflammation in adipose tissue via both suppression of macrophage infiltration and
503 acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-
504 induced obese mice. *Exerc Immunol Rev*. 2010;16:105-18.
505 49. Shan B, Shao M, Zhang Q, et al. Perivascular mesenchymal cells control adipose-
506 tissue macrophage accrual in obesity. *Nat Metab*. Nov 2020;2(11):1332-1349.
507 50. Orr JS, Puglisi MJ, Ellacott KL, Lumeng CN, Wasserman DH, Hasty AH. Toll-
508 like receptor 4 deficiency promotes the alternative activation of adipose tissue
509 macrophages. *Diabetes*. Nov 2012;61(11):2718-27.
510 51. Griffin C, Eter L, Lanzetta N, et al. TLR4, TRIF, and MyD88 are essential for
511 myelopoiesis and CD11c(+) adipose tissue macrophage production in obese mice. *J*
512 *Biol Chem*. Jun 8 2018;293(23):8775-8786.
513 52. Rendra E, Riabov V, Mossel DM, Sevastyanova T, Harmsen MC, Kzhyshkowska
514 J. Reactive oxygen species (ROS) in macrophage activation and function in diabetes.
515 *Immunobiology*. Mar 2019;224(2):242-253.
516 53. Xia W, Lu Z, Chen W, Zhou J, Zhao Y. Excess fatty acids induce pancreatic
517 acinar cell pyroptosis through macrophage M1 polarization. *BMC Gastroenterol*. Feb
518 19 2022;22(1):72.
519 54. Yuan Y, Chen Y, Peng T, et al. Mitochondrial ROS-induced lysosomal

520 dysfunction impairs autophagic flux and contributes to M1 macrophage polarization
521 in a diabetic condition. *Clin Sci (Lond)*. Aug 15 2019;133(15):1759-1777.
522 55. Acin-Perez R, Iborra S, Marti-Mateos Y, et al. Fgr kinase is required for
523 proinflammatory macrophage activation during diet-induced obesity. *Nat Metab*. Sep
524 2020;2(9):974-988.
525 56. Li W, Zeng H, Xu M, et al. Oleanolic Acid Improves Obesity-Related
526 Inflammation and Insulin Resistance by Regulating Macrophages Activation. *Front*
527 *Pharmacol*. 2021;12:697483.
528 57. Wang Y, Tang B, Long L, et al. Improvement of obesity-associated disorders by a
529 small-molecule drug targeting mitochondria of adipose tissue macrophages. *Nat*
530 *Commun*. Jan 4 2021;12(1):102.
531 58. Holmstrom KM, Finkel T. Cellular mechanisms and physiological consequences
532 of redox-dependent signalling. *Nat Rev Mol Cell Biol*. Jun 2014;15(6):411-21.
533 59. Kausar S, Wang F, Cui H. The Role of Mitochondria in Reactive Oxygen Species
534 Generation and Its Implications for Neurodegenerative Diseases. *Cells*. Dec 17
535 2018;7(12).
536 60. Yang Z, Min Z, Yu B. Reactive oxygen species and immune regulation. *Int Rev*
537 *Immunol*. 2020;39(6):292-298.
538 61. Appari M, Channon KM, McNeill E. Metabolic Regulation of Adipose Tissue
539 Macrophage Function in Obesity and Diabetes. *Antioxid Redox Signal*. Jul 20
540 2018;29(3):297-312.
541 62. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in
542 adipose tissue macrophage polarization. *J Clin Invest*. Jan 2007;117(1):175-84.
543 63. Shin KC, Hwang I, Choe SS, et al. Macrophage VLDLR mediates obesity-
544 induced insulin resistance with adipose tissue inflammation. *Nat Commun*. Oct 20
545 2017;8(1):1087.
546 64. Shields JM, Christy RJ, Yang VW. Identification and characterization of a gene
547 encoding a gut-enriched Kruppel-like factor expressed during growth arrest. *J Biol*
548 *Chem*. Aug 16 1996;271(33):20009-17.
549 65. McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and
550 diseases. *Physiol Rev*. Oct 2010;90(4):1337-81.
551 66. Feinberg MW, Cao Z, Wara AK, Lebedeva MA, Senbanerjee S, Jain MK.
552 Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. *J*
553 *Biol Chem*. Nov 18 2005;280(46):38247-58.
554 67. Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage
555 polarization. *J Clin Invest*. Jul 2011;121(7):2736-49.
556 68. Pan Y, Hui X, Hoo RLC, et al. Adipocyte-secreted exosomal microRNA-34a
557 inhibits M2 macrophage polarization to promote obesity-induced adipose
558 inflammation. *J Clin Invest*. Feb 1 2019;129(2):834-849.
559 69. Qiu Y, Xu J, Yang L, et al. MiR-375 silencing attenuates pro-inflammatory
560 macrophage response and foam cell formation by targeting KLF4. *Exp Cell Res*. Mar
561 1 2021;400(1):112507.
562 70. Luan B, Yoon YS, Le Lay J, Kaestner KH, Hedrick S, Montminy M. CREB
563 pathway links PGE2 signaling with macrophage polarization. *Proc Natl Acad Sci U S*

564 *A*. Dec 22 2015;112(51):15642-7.
565 71. Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN.
566 Thiazolidinediones as antidiabetic agents: A critical review. *Bioorg Chem*. Apr
567 2018;77:548-567.
568 72. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-
569 activated receptor-gamma is a negative regulator of macrophage activation. *Nature*.
570 Jan 1 1998;391(6662):79-82.
571 73. Chawla A. Control of macrophage activation and function by PPARs. *Circ Res*.
572 May 28 2010;106(10):1559-69.
573 74. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization:
574 enabling diversity with identity. *Nat Rev Immunol*. Oct 25 2011;11(11):750-61.
575 75. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific
576 PPARgamma controls alternative activation and improves insulin resistance. *Nature*.
577 Jun 28 2007;447(7148):1116-20.
578 76. Kiran S, Rakib A, Kodidela S, Kumar S, Singh UP. High-Fat Diet-Induced
579 Dysregulation of Immune Cells Correlates with Macrophage Phenotypes and Chronic
580 Inflammation in Adipose Tissue. *Cells*. Apr 13 2022;11(8).
581 77. Li C, Ying W, Huang Z, et al. IRF6 Regulates Alternative Activation by
582 Suppressing PPARgamma in Male Murine Macrophages. *Endocrinology*. Sep 1
583 2017;158(9):2837-2847.
584 78. Xu J, Dong J, Ding H, et al. Ginsenoside compound K inhibits obesity-induced
585 insulin resistance by regulation of macrophage recruitment and polarization via
586 activating PPARgamma. *Food Funct*. Mar 21 2022;13(6):3561-3571.
587 79. Saltiel AR. Insulin signaling in health and disease. *J Clin Invest*. Jan 4
588 2021;131(1).
589 80. Rahman MS, Hossain KS, Das S, et al. Role of Insulin in Health and Disease: An
590 Update. *Int J Mol Sci*. Jun 15 2021;22(12).
591 81. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of
592 insulin receptor signalling. *Nat Rev Mol Cell Biol*. Jan 2018;19(1):31-44.
593 82. Jaldin-Fincati JR, Pavarotti M, Frendo-Cumbo S, Bilan PJ, Klip A. Update on
594 GLUT4 Vesicle Traffic: A Cornerstone of Insulin Action. *Trends Endocrinol Metab*.
595 Aug 2017;28(8):597-611.
596 83. Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic
597 Strategies. *Diabetes Metab J*. Jan 2022;46(1):15-37.
598 84. Chattopadhyay D, Das S, Guria S, Basu S, Mukherjee S. Fetuin-A regulates
599 adipose tissue macrophage content and activation in insulin resistant mice through
600 MCP-1 and iNOS: involvement of IFNgamma-JAK2-STAT1 pathway. *Biochem J*.
601 Nov 26 2021;478(22):4027-4043.
602 85. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. *Annu*
603 *Rev Physiol*. 2010;72:219-46.
604 86. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor
605 necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
606 *Am J Physiol Endocrinol Metab*. May 2001;280(5):E745-51.
607 87. Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in

608 Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. *J*
609 *Cell Biochem*. Jan 2018;119(1):105-110.
610 88. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose
611 tissue-derived cytokines: in vivo and in vitro investigations in humans. *Am J Physiol*
612 *Endocrinol Metab*. Sep 2003;285(3):E527-33.
613 89. Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose
614 tissue, and adiponectin in metabolic syndrome. *J Clin Invest*. Oct 1
615 2019;129(10):4041-4049.
616 90. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of
617 the underlying molecular mechanisms. *J Cell Physiol*. Jun 2019;234(6):8152-8161.
618 91. Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of
619 type 2 diabetes. *Inflammopharmacology*. Jun 2018;26(3):685-698.
620 92. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and
621 SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of
622 insulin receptor substrate proteins by discrete mechanisms. *Mol Cell Biol*. Jun
623 2004;24(12):5434-46.
624 93. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in
625 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in
626 human fat cells from insulin-resistant subjects. *J Biol Chem*. Nov 14
627 2003;278(46):45777-84.
628 94. Lira FS, Rosa JC, Dos Santos RV, et al. Visceral fat decreased by long-term
629 interdisciplinary lifestyle therapy correlated positively with interleukin-6 and tumor
630 necrosis factor-alpha and negatively with adiponectin levels in obese adolescents.
631 *Metabolism*. Mar 2011;60(3):359-65.
632 95. Stanford KI, Middelbeek RJ, Townsend KL, et al. Brown adipose tissue regulates
633 glucose homeostasis and insulin sensitivity. *J Clin Invest*. Jan 2013;123(1):215-23.
634 96. Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ. Induction of
635 uncoupling protein 1 by central interleukin-6 gene delivery is dependent on
636 sympathetic innervation of brown adipose tissue and underlies one mechanism of
637 body weight reduction in rats. *Neuroscience*. 2002;115(3):879-89.
638
639



640

641 Figure 1: “Crown-like structures (CLS) ” in adipose tissue. Macrophages surround the
642 necrotic adipocytes and form “CLS”. During this process, recruited macrophages are
643 predominantly of the M1 phenotype, and secrete a variety of pro-inflammatory
644 factors. Therefore, “CLS” is considered as one of the hallmarks of adipose tissue
645 inflammation.

646



647

648 Figure 2: Plasticity of macrophage phenotypes. Macrophages exhibit different
649 phenotypes and perform their respective functions in response to different stimuli. M1
650 macrophages mainly show pro-inflammatory effects, whereas M2 macrophages
651 (including M2a, 2b, 2c, and 2d) mainly show anti-inflammatory effects and promote
652 tissue repair. IFN-γ = interferon-γ; LPS = lipopolysaccharide; TNF = tumor necrosis
653 factor; IL = interleukin; TGF-β = transforming growth factor-β; ICs = immune
654 complexes; TLR = Toll-like receptor; IL-1R = interleukin-1 receptor; A2R = A2
655 adenosine receptor.
656
657
658



659
660 Figure 3: Insulin signaling pathway. The binding of insulin to the receptor causes
661 phosphorylation of insulin receptor substrate(IRS), after which the catalytic activity of
662 PI3K is activated, leading to the activation of Akt, which mediates glucose transport
663 through glucose transporter 4 (GLUT4). Meanwhile, activated Akt continues to
664 activate downstream signaling pathways to regulate glucose homeostasis. It is worth
665 mentioning that in adipose tissue, the inhibition of lipolysis and gluconeogenesis by
666 insulin may be associated with phosphodiesterase 3B(PDE3B), protein phosphatase
667 1(PP1), and protein phosphatase 2A (PP2A). IRS = insulin receptor substrate; PI3K =
668 phosphatidylinositol 3 kinase; PIP2 = phosphatidylinositol 4,5-bisphosphate; PIP3 =
669 phosphatidylinositol 3,4,5-trisphosphate; PDK1 = phosphoinositide-dependent protein
670 kinase 1; PDE3B = phosphodiesterase 3B; PP1 = protein phosphatase 1; PP2A =
671 protein phosphatase 2A; GLUT4 = glucose transporter 4.
672